Mitsubishi Tanabe Pharma Highlights Key Parkinson's Research
Mitsubishi Tanabe Pharma Showcases Innovative Research
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is proud to announce its participation at the upcoming 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD). This significant event will be a platform for MTPA to present two important poster presentations focusing on the investigational drug ND0612, dedicated to addressing Parkinson's disease (PD).
Understanding ND0612's Role in Parkinson's Disease Treatment
ND0612 is a pioneering therapy aimed at providing continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for patients battling motor fluctuations associated with Parkinson's disease. By continuously supplying these crucial medications, ND0612 seeks to enhance patient experiences and improve their quality of life.
Presenting at IAPRD: Key Findings
At this significant congress, MTPA will share findings from the pivotal Phase 3 BouNDless trial, which delves deep into the effects of ND0612 on individuals diagnosed with Parkinson's disease. These valuable insights will focus on patient-reported outcomes that assess daily motor performance and the efficacy of 24-hour treatment regimens as recorded in patient home diaries.
Highlights of the Presentations
- Effect of ND0612 Continuous Infusion on Motor Performance and Experiences of Daily Living in Patients with Parkinson's Disease (Rebecca Vayalumkal, PharmD, RPh; MTPA)
- Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Daily Motor State Characteristics of Patients with Parkinson's Disease Experiencing Motor Fluctuations (Rebecca Vayalumkal, PharmD, RPh; MTPA)
About MTPA and Its Commitment
Mitsubishi Tanabe Pharma America is committed to advancing therapeutic solutions that transform the lives of patients facing complex health challenges. The company's innovative pipeline reflects a deep commitment to research and development in the neurological field, working tirelessly to enhance treatment strategies for various conditions, including Parkinson's Disease.
Enhancing Patient Life Quality with Innovative Solutions
As a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Jersey City, MTPA is dedicated to both developing new therapies and commercializing effective pharmaceutical products across North America. This commitment is exemplified through the company’s rigorous pursuit of therapeutic innovation that aims to improve patient outcomes.
About NeuroDerm and Collaborative Efforts
NeuroDerm, Ltd., also under the umbrella of Mitsubishi Tanabe Pharma Corporation, plays a pivotal role in the development of ND0612. With a focus on reducing the disease burden and improving patient quality of life, NeuroDerm is committed to creating next-generation solutions that fuse pharmaceutical advancements with cutting-edge medical technology.
Future Directions in Parkinson's Disease Treatment
The pharmaceutical landscape is rapidly evolving, and Mitsubishi Tanabe Pharma recognizes the importance of staying at the forefront of these changes. The ongoing research into ND0612 highlights a proactive approach to understanding patient needs and how best to address them through innovative therapies that are precisely tailored to varying individual conditions.
Frequently Asked Questions
What is ND0612?
ND0612 is an investigational drug-device combination therapy providing continuous subcutaneous infusion of liquid levodopa/carbidopa aimed at treating motor fluctuations in Parkinson's disease patients.
When will the presentations occur?
The presentations will take place during the 30th World Congress on Parkinson's Disease and Related Disorders, specifically during the Guided Poster Tour on a designated day of the congress.
Who is presenting the findings?
Rebecca Vayalumkal, PharmD, RPh, from MTPA, will be presenting the findings related to ND0612 and its impact on Parkinson's disease patients.
What is the significance of the BouNDless trial?
The BouNDless trial is a pivotal Phase 3 study that assesses the effectiveness of ND0612 in addressing motor fluctuations in Parkinson's disease, providing crucial insights into patient experiences and treatment outcomes.
How can I learn more about Mitsubishi Tanabe Pharma America?
For more information, you can explore MTPA's website and various social media channels to stay updated on their latest advancements and initiatives.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.